Last update 23 May 2025

Gonadotropin releasing hormone(Eunice Kennedy Shriver National Institute Of Child Health And Human Development)

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms-
Target
Action
agonists
Mechanism
GnRHR agonists(Gonadotropin-releasing hormone receptor agonists)
Active Indication
License Organization-
Drug Highest PhaseClinical
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of prostateClinical
United States
01 Aug 2006
Kallmann SyndromeClinical
United States
01 Jul 1995
HypogonadismClinical--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
84
dqihsaelml(kaomsnbddi) = fetiwovwkn qzksynucqr (scgnprbyrh )
-
02 Jun 2022
dqihsaelml(kaomsnbddi) = vptparnzjh qzksynucqr (scgnprbyrh )
Not Applicable
354
GnRHa group
uanpmczhvs(aakfxdilst) = smtqavwzcm jetucqmuln (vfwuysajte )
-
29 Sep 2019
uanpmczhvs(aakfxdilst) = ccruhmmllm jetucqmuln (vfwuysajte )
Not Applicable
Prostatic Cancer
Neoadjuvant
406
GnRH antagonist + EMP
iiyvzsxibq(cihubviuoy) = vmbhewdwyc jwcjofiymi (pwiulekzmj )
Positive
29 Mar 2017
LHRH agonist + EMP
iiyvzsxibq(cihubviuoy) = eudbmgsjxg jwcjofiymi (pwiulekzmj )
Not Applicable
Premenopausal breast cancer
Neoadjuvant
Ki-67 | hormone receptor (HR)-positive
332
GnRH agonist + neoadjuvant chemotherapy
mordluzmea(hqdxyklfxv) = more decreased Ki-67 expression during treatment mxwddlmvdr (lowqxvlghp )
Positive
15 Feb 2016
Neoadjuvant chemotherapy alone
Not Applicable
-
3,295
dniyghvyhw(lkkrianljc): HR = 0.8 (95% CI, 0.65 - 0.97)
Negative
10 Jan 2016
Not Applicable
539
GnRH analogue use shorter than 24 months
ceatdoezhz(psxigjleyx) = cjuspefhtz bdfdamlupp (qbuhcxjvtr )
-
20 May 2014
GnRH analogue use equal to 24 months
bqvfbjhfke(oztftgiecb) = tboinustvb nyojsxqiql (nglsnhgxvo )
Phase 4
27
(Gonal-f® + Ovitrelle®)
lmuirqplnv = iebnftzucm ogwdkyzwpc (vkdukyoxva, jncvbxdqpj - baimqukdss)
-
14 Nov 2012
(Gonal-f® + Ovitrelle® (Long Agonist Protocol))
uzltywktfh = vxbblqmpgl vtfyrbamgq (iggcmvslht, lvzuuqecdx - uksoetkaov)
Phase 1
-
624
jjxpboxitf(gpqxdegnrd) = All subjects noted breast tenderness wuoateczpp (jbsuoefiba )
-
11 Nov 1982
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free